In the last years, evidence showing lower bioavailability of enterosolvent acetylsalicylic acid (ecASA) has accumulated. At the same time, lower to absent prophylactic antithrombotic effect of ecASA has been documented.
Despite these data, ecASA is preferred by many health care payers in their positive lists.